The doctors consider mSMART classification to look at high-, intermediate-, and standard-risk myeloma. They discuss, with the increasing depth of response in myeloma with the newer drugs, how doctors should evaluate the use of these drugs with the higher-risk disease groups.
IMWG Myeloma Experts debate the latest trends in treatment
June 9, 2016
Copenhagen, Denmark
